Blockade of Syk ameliorates the development of murine sclerodermatous chronic graft-versus-host disease

Journal of Dermatological Science

Volumn 74, Issue 3, 2014, Pages 214-221

  Le Huu, Doanh ^a,b   Kimura, Hiroshi ^a   Date, Mutsumi ^a   Hamaguchi, Yasuhito ^a   Hasegawa, Minoru ^c   Hau, Khang Tran ^b   Fujimoto, Manabu ^d   Takehara, Kazuhiko ^a   Matsushita, Takashi ^a  

^a KANAZAWA UNIVERSITY   (Japan)

^b HANOI MEDICAL UNIVERSITY   (Viet Nam)

^c UNIVERSITY OF FUKUI   (Japan)

^d UNIVERSITY OF TSUKUBA   (Japan)

Author keywords

Chronic GVHD; CXCR4; Memory T cells; Syk; Systemic sclerosis

Indexed keywords

CHEMOKINE RECEPTOR CXCR4; FOSTAMATINIB; GAMMA INTERFERON; INTERLEUKIN 13; INTERLEUKIN 17; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; PROTEIN KINASE SYK; RANTES; STROMAL CELL DERIVED FACTOR 1; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA; CHEMOKINE; CXCR4 PROTEIN, MOUSE; OXAZINE DERIVATIVE; PROTEIN TYROSINE KINASE; PYRIDINE DERIVATIVE; SIGNAL PEPTIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; B LYMPHOCYTE; BONE MARROW TRANSPLANTATION; CD11B+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CELL PROLIFERATION; CHRONIC GRAFT VERSUS HOST DISEASE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE SEVERITY; DOWN REGULATION; ENZYME PHOSPHORYLATION; FEMALE; FIBROSIS; GENE EXPRESSION; IN VITRO STUDY; MALE; MEMORY CD4+ T LYMPHOCYTE; MEMORY T LYMPHOCYTE; MONOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCLERODERMA; SCLERODERMATOUS CHRONIC GRAFT VERSUS HOST DISEASE; T LYMPHOCYTE; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; DISEASE MODEL; DRUG EFFECTS; DRUG SCREENING; GRAFT VS HOST DISEASE; IMMUNOLOGY; METABOLISM; SCLERODERMA, SYSTEMIC;

ANIMALS; B-LYMPHOCYTES; BONE MARROW TRANSPLANTATION; CHEMOKINES; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; FEMALE; GRAFT VS HOST DISEASE; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MICE, INBRED BALB C; MONOCYTES; OXAZINES; PROTEIN-TYROSINE KINASES; PYRIDINES; RECEPTORS, CXCR4; SCLERODERMA, SYSTEMIC; T-LYMPHOCYTES;

EID: 84899912860     PISSN: 09231811     EISSN: 1873569X     Source Type: Journal    
DOI: 10.1016/j.jdermsci.2014.02.008     Document Type: Article

References (51)

1. Varga J., Abraham D. Systemic sclerosis: a prototypic multisystem fibrotic disorder. Journal of Clinical Investigation 2007, 117:557-567.
2. Abraham D.J., Krieg T., Distler J., Distler O. Overview of pathogenesis of systemic sclerosis. Rheumatology 2009, 48(Suppl. 3):iii3-iii7.
3. + T cells do not induce graft-versus-host disease. Journal of Clinical Investigation 2003, 112:101-108.
4. Le Huu D., Matsushita T., Jin G., Hamaguchi Y., Hasegawa M., Takehara K., et al. Donor-derived regulatory B cells are important for suppression of murine sclerodermatous chronic graft-versus-host disease. Blood 2013, 121:3274-3283.
5. Wong B.R., Grossbard E.B., Payan D.G., Masuda ES: Targeting Syk as a treatment for allergic and autoimmune disorders. Expert Opinion on Investigational Drugs 2004, 13:743-762.
6. Arimitsu N., Shimizu J., Fujiwara N., Takai K., Takada E., Kono T., et al. Role of SDF1/CXCR4 interaction in experimental hemiplegic models with neural cell transplantation. International Journal of Molecular Sciences 2012, 13:2636-2649.
7. Wang L., Gordon R.A., Huynh L., Su X., Park Min K.H., Han J., et al. Indirect inhibition of Toll-like receptor and type I interferon responses by ITAM-coupled receptors and integrins. Immunity 2010, 32:518-530.
8. Buchner M., Baer C., Prinz G., Dierks C., Burger M., Zenz T., et al. Spleen tyrosine kinase inhibition prevents chemokine- and integrin-mediated stromal protective effects in chronic lymphocytic leukemia. Blood 2010, 115:4497-4506.
9. Schymeinsky J., Gerstl R., Mannigel I., Niedung K., Frommhold D., Panthel K., et al. A fundamental role of mAbp1 in neutrophils: impact on beta(2) integrin-mediated phagocytosis and adhesion in vivo. Blood 2009, 114:4209-4220.
10. Pamuk O.N., Lapchak P.H., Rani P., Pine P., Dalle Lucca J.J., Tsokos G.C. Spleen tyrosine kinase inhibition prevents tissue damage after ischemia-reperfusion. American Journal of Physiology Gastrointestinal and Liver Physiology 2010, 299:G391-G399.
11. Bahjat F.R., Pine P.R., Reitsma A., Cassafer G., Baluom M., Grillo S., et al. An orally bioavailable spleen tyrosine kinase inhibitor delays disease progression and prolongs survival in murine lupus. Arthritis and Rheumatism 2008, 58:1433-1444.
12. Blease K. Targeting kinases in asthma. Expert Opinion on Investigational Drugs 2005, 14:1213-1220.
13. Oda A., Ochs H.D., Lasky L.A., Spencer S., Ozaki K., Fujihara M., et al. CrkL is an adapter for Wiskott-Aldrich syndrome protein and Syk. Blood 2001, 97:2633-2639.
14. Mazuc E., Villoutreix B.O., Malbec O., Roumier T., Fleury S., Leonetti J.P., et al. A novel druglike spleen tyrosine kinase binder prevents anaphylactic shock when administered orally. Journal of Allergy and Clinical Immunology 2008, 122:188-194. 194.e1-3.
15. Leseux L., Hamdi S.M., Al Saati T., Capilla F., Recher C., Laurent G., et al. Syk-dependent mTOR activation in follicular lymphoma cells. Blood 2006, 108:4156-4162.
16. Coopman P.J., Do M.T., Barth M., Bowden E.T., Hayes A.J., Basyuk E., et al. The Syk tyrosine kinase suppresses malignant growth of human breast cancer cells. Nature 2000, 406:742-747.
17. Leonhardt F., Zirlik K., Buchner M., Prinz G., Hechinger A.K., Gerlach U.V., et al. Spleen tyrosine kinase (Syk) is a potent target for GvHD prevention at different cellular levels. Leukemia: Official Journal of the Leukemia Society of America, Leukemia Research Fund, UK 2012, 26:1617-1629.
18. Bajpai M. Fostamatinib, a Syk inhibitor prodrug for the treatment of inflammatory diseases. IDrugs: the Investigational Drugs Journal 2009, 12:174-185.
19. Kyttaris V.C., Tsokos G.C. Syk kinase as a treatment target for therapy in autoimmune diseases. Clinical Immunology 2007, 124:235-237.
20. Denyer J., Patel V. Syk kinase inhibitors in allergic diseases. Drug News & Perspectives 2009, 22:146-150.
21. Podolanczuk A., Lazarus A.H., Crow A.R., Grossbard E., Bussel J.B. Of mice and men: an open-label pilot study for treatment of immune thrombocytopenic purpura by an inhibitor of Syk. Blood 2009, 113:3154-3160.
22. Sheridan C. Small molecule challenges dominance of TNF-alpha inhibitors. Nature Biotechnology 2008, 26:143-144.
23. Cha H.S., Boyle D.L., Inoue T., Schoot R., Tak P.P., Pine P., et al. A novel spleen tyrosine kinase inhibitor blocks c-Jun N-terminal kinase-mediated gene expression in synoviocytes. Journal of Pharmacology and Experimental Therapeutics 2006, 317:571-578.
24. Wang H., Malbon C.C. G(s)alpha repression of adipogenesis via Syk. Journal of Biological Chemistry 1999, 274:32159-32166.
25. Le Huu D., Matsushita T., Jin G., Hamaguchi Y., Hasegawa M., Takehara K., et al. IL-6 blockade attenuates the development of murine sclerodermatous chronic graft-versus-host disease. Journal of Investigative Dermatology 2012, 132:2752-2761.
26. + T cells do not induce graft-versus-host disease. Journal of Clinical Investigation 2003, 112:101-108.
27. Yanagi S., Inatome R., Takano T., Yamamura H. Syk expression and novel function in a wide variety of tissues. Biochemical and Biophysical Research Communications 2001, 288:495-498.
28. Lapidot T., Dar A., Kollet O. How do stem cells find their way home?. Blood 2005, 106:1901-1910.
29. Matsusaka S., Tohyama Y., He J., Shi Y., Hazama R., Kadono T., et al. Protein-tyrosine kinase, Syk, is required for CXCL12-induced polarization of B cells. Biochemical and Biophysical Research Communications 2005, 328:1163-1169.
30. Dutt S., Tseng D., Ermann J., George T.I., Liu Y.P., Davis C.R., et al. Naive and memory T cells induce different types of graft-versus-host disease. Journal of Immunology 2007, 179:6547-6554.
31. Chandok M.R., Okoye F.I., Ndejembi M.P., Farber D.L. A biochemical signature for rapid recall of memory CD4 T cells. Journal of Immunology 2007, 179:3689-3698.
32. Zhou L., Askew D., Wu C., Gilliam A.C. Cutaneous gene expression by DNA microarray in murine sclerodermatous graft-versus-host disease, a model for human scleroderma. Journal of Investigative Dermatology 2007, 127:281-292.
33. Zhang Y., McCormick L.L., Desai S.R., Wu C., Gilliam A.C. Murine sclerodermatous graft-versus-host disease, a model for human scleroderma: cutaneous cytokines, chemokines, and immune cell activation. Journal of Immunology 2002, 168:3088-3098.
34. Cornall R.J., Cheng A.M., Pawson T., Goodnow C.C. Role of Syk in B-cell development and antigen-receptor signaling. Proceedings of the National Academy of Sciences of the United States of America 2000, 97:1713-1718.
35. Palacios E.H., Weiss A. Distinct roles for Syk and ZAP-70 during early thymocyte development. Journal of Experimental Medicine 2007, 204:1703-1715.
36. Anderson B.E., Tang A.L., Wang Y., Froicu M., Rothstein D., McNiff J.M., et al. Enhancing alloreactivity does not restore GVHD induction but augments skin graft rejection by CD4(+) effector memory T cells. European Journal of Immunology 2011, 41:2782-2792.
37. + T cell memory. Journal of Immunology 2009, 182:1868-1876.
38. Baggiolini M. Chemokines and leukocyte traffic. Nature 1998, 392:565-568.
39. Le Huu D., Matsushita T., Jin G., Hamaguchi Y., Hasegawa M., Takehara K., et al. FTY720 ameliorates murine sclerodermatous chronic graft-versus-host disease by promoting expansion of splenic regulatory cells and inhibiting immune cell infiltration into skin. Arthritis and Rheumatism 2013, 65:1624-1635.
40. Moll N.M., Ransohoff RM: CXCL12 and CXCR4 in bone marrow physiology. Expert Review of Hematology 2010, 3:315-322.
41. Salcedo R., Oppenheim J.J. Role of chemokines in angiogenesis: CXCL12/SDF-1 and CXCR4 interaction, a key regulator of endothelial cell responses. Microcirculation 2003, 10:359-370.
42. Cipriani P., Franca Milia A., Liakouli V., Pacini A., Manetti M., Marrelli A., et al. Differential expression of stromal cell-derived factor 1 and its receptor CXCR4 in the skin and endothelial cells of systemic sclerosis patients: pathogenetic implications. Arthritis and Rheumatism 2006, 54:3022-3033.
43. Manetti M., Liakouli V., Fatini C., Cipriani P., Bonino C., Vettori S., et al. Association between a stromal cell-derived factor 1 (SDF-1/CXCL12) gene polymorphism and microvascular disease in systemic sclerosis. Annals of the Rheumatic Diseases 2009, 68:408-411.
44. Ozaki N., Suzuki S., Ishida M., Harada Y., Tanaka K., Sato Y., et al. Syk-dependent signaling pathways in neutrophils and macrophages are indispensable in the pathogenesis of anti-collagen antibody-induced arthritis. International Immunology 2012, 24:539-550.
45. Chu Y.W., Gress R.E. Murine models of chronic graft-versus-host disease: insights and unresolved issues. Biology of Blood and Marrow Transplantation: Journal of the American Society for Blood and Marrow Transplantation 2008, 14:365-378.
46. Kitaba S., Murota H., Terao M., Azukizawa H., Terabe F., Shima Y., et al. Blockade of interleukin-6 receptor alleviates disease in mouse model of scleroderma. American Journal of Pathology 2012, 180:165-176.
47. Okamoto Y., Hasegawa M., Matsushita T., Hamaguchi Y., Huu D.L., Iwakura Y., et al. Potential roles of interleukin-17A in the development of skin fibrosis in mice. Arthritis and Rheumatism 2012, 64:3726-3735.
48. Hill G.R., Olver S.D., Kuns R.D., Varelias A., Raffelt N.C., Don A.L., et al. Stem cell mobilization with G-CSF induces type 17 differentiation and promotes scleroderma. Blood 2010, 116:819-828.
49. + T cells is critical for the pathogenesis of chronic sclerodermatous graft-versus-host disease in a murine model. Journal of Immunology 2010, 184:764-774.
50. Skhirtladze C., Distler O., Dees C., Akhmetshina A., Busch N., Venalis P., et al. Src kinases in systemic sclerosis: central roles in fibroblast activation and in skin fibrosis. Arthritis and Rheumatism 2008, 58:1475-1484.
51. El-Hillal O., Kurosaki T., Yamamura H., Kinet J.P., Scharenberg AM: Syk kinase activation by a src kinase-initiated activation loop phosphorylation chain reaction. Proceedings of the National Academy of Sciences of the United States of America 1997, 94:1919-1924.